Frontiers | Antibodies and Immunity During Kawasaki Disease
Rheumato | Free Full-Text | Kawasaki Disease: Management Challenges during COVID-19 Pandemic with an Upsurge in Multisystem Inflammatory Syndrome in Children
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
Children | Free Full-Text | Major Complication Following Kawasaki Disease in an Infant—The Development of Apical Infarction and Aneurysm Formation
Clinical characteristics of patients with recurrent Kawasaki disease: a nationwide cohort study of 19 456 patients with minimum 3-year follow up | Archives of Disease in Childhood
Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease | Italian Journal of Pediatrics | Full Text
Kawasaki Disease
Kawasaki disease recurrence in the COVID-19 era: a systematic review of the literature | Italian Journal of Pediatrics | Full Text
Kawasaki disease: pathophysiology and insights from mouse models | Nature Reviews Rheumatology
Mortality among Children with Kawasaki Disease in Japan | NEJM
Frontiers | How Should We Classify Kawasaki Disease?
Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution | PLOS ONE
Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial - The Lancet Child & Adolescent Health
Recurrent Kawasaki disease | British Dental Journal
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association | Circulation
Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study | Journal of the American Heart Association
Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease | Scientific Reports
Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a
Frontiers | How Should We Classify Kawasaki Disease?
Frontiers | Kawasaki Disease
Recurrent Kawasaki disease presenting as acute airway obstruction
Epidemiologic features of Kawasaki disease in acute stages in Taiwan, 1997–2010: Effect of different case definitions in claims data analysis - ScienceDirect
Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease - ScienceDirect
Frontiers | Kawasaki Disease
